Drug intelligence / Profile preview

WJ02

Development stage: Preclinical
Lead developer: Wigen Biomedicine Technology
Modality: Small Molecules
Administration: Oral

Overview

WJ02 is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) being developed by Wigen Biomedicine Technology (Shanghai). It is designed to target EGFR-mutant cancers, which are common drivers in malignancies such as non-small cell lung cancer (NSCLC). By binding to the kinase domain of EGFR, WJ02 inhibits the downstream signaling pathways that promote tumor cell proliferation and survival. The drug is currently in the early stages of development for oncology indications, aiming to provide a therapeutic option for patients with specific EGFR mutations.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on WJ02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WJ02.

Explore the full profile